RESOMER RG 502 H Bioresorbable PLGA Drug Delivery Grade is a poly(D,L-lactide-co-glycolide) copolymer with a 50:50 molar lactide:glycolide ratio, free carboxylic acid end groups, and a low-viscosity specification that positions it for solvent-based microencapsulation, nanoparticle formation, and short-duration implantable depot systems. The PLGA backbone is identified by CAS 26780-50-7; the H suffix in the grade name designates acid termination, whereas the corresponding ester-terminated grade is designated RG 502. Typical release-control specification values include an inherent viscosity of 0.16–0.24 dL/g measured as a 0.1% w/v solution in chloroform at 25 °C using ISO 1628-1 or ASTM D2857, and a glass transition temperature of 42–46 °C determined by differential scanning calorimetry according to ISO 11357-2. Residual moisture is normally specified below 0.5% by Karl Fischer titration per USP ⟨921⟩, and residual monomer content is typically reported below 0.5% on vendor certificates of analysis.

The material is soluble in dichloromethane, chloroform, acetone, and ethyl acetate, and is insoluble in water. This solubility profile allows oil-in-water emulsification, organic-phase coacervation, spray drying, and phase-inversion processing without high-temperature melt extrusion. The low inherent viscosity lowers the organic-phase viscosity of polymer solutions, which can support filtration through 0.2 µm membranes when dilute solutions in the 5–10 wt% range are used. The same low viscosity limits melt strength and makes the grade less suitable for load-bearing injection-molded implants than higher-viscosity PLGA grades.

What Distinguishes Acid-Terminated RG 502 H from Ester-Terminated RG 502?

The terminal functionality is the controlling structural difference between RG 502 H and RG 502. RG 502 H carries free carboxylic acid end groups; RG 502 carries ester end groups. The acid terminus increases water uptake and reduces the initial hydrophobic surface character of the matrix, which shortens the induction period before mass loss begins. In phosphate-buffered saline at pH 7.4 and 37 °C, acid-terminated 50:50 PLGA generally degrades faster than an ester-terminated 50:50 PLGA of equivalent inherent viscosity. This is not a compliance defect but a formulation tool: the acid-terminated grade is selected when rapid hydrolytic resorption is required, and the ester-terminated grade is selected when slower water penetration or reduced initial acid load is preferred.

The difference is particularly relevant for acid-labile active pharmaceutical ingredients. Carboxylic acid end groups can lower the local pH within the polymer matrix during hydrolytic degradation, and the resulting microclimate can promote degradation of proton-sensitive peptides, esters, or acid-labile small molecules. For amine-containing drugs, the acid end groups can form salt or ion-pair structures that alter encapsulation efficiency and release kinetics. In such cases, ester-terminated RG 502 may provide a more inert matrix environment, although release must still be confirmed because PLGA hydrolysis generates carboxylic acid groups regardless of the initial end-group state.

Viscosity, Glass Transition, and Molecular Weight Bands in the RG 50x H Series

Inherent viscosity is the primary specification that differentiates RG 502 H from higher-viscosity acid-terminated grades such as RG 503 H and RG 504 H. The 0.16–0.24 dL/g band for RG 502 H corresponds approximately to a reported weight-average molecular weight range of 7,000–17,000 g/mol in vendor literature, though batch-to-batch polydispersity influences degradation and release behavior. Because molecular weight is not a compendial release parameter for this polymer, viscosity-controlled specification bands are used to maintain lot-to-lot consistency. The glass transition temperature of 42–46 °C places the material close to ambient processing temperatures; long-term storage is therefore maintained at −20 °C with desiccant protection because moisture uptake above 0.5% initiates hydrolysis even in the solid state.

In pharmaceutical development, the glass transition has practical consequences for liquid handling and drying. Spray-dried powders produced from acetone or ethyl acetate solutions require outlet temperatures below 40 °C to avoid particle coalescence, because the operating temperature approaches the polymer glass transition. The inlet temperature window is typically held between 45 °C and 65 °C, and the outlet temperature is controlled by feed rate and gas flow. This narrow window is a process conflict: higher inlet temperature improves solvent evaporation but pushes the outlet temperature toward the glass transition, while lower inlet temperature reduces evaporation and increases residual solvent. The acid end groups do not eliminate this thermorheological boundary; they are relevant mainly to degradation and water interaction, not to the glass transition itself.

The low inherent viscosity of RG 502 H also reduces organic-phase viscosity in microencapsulation. A 20 wt% solution in dichloromethane has a significantly lower dynamic viscosity than a 20 wt% solution of RG 503 H, which reduces the required emulsification shear and lowers motor torque on production rotor-stator dispersers. This is critical when scaling from laboratory batch to production-scale mixers because lower torque permits longer continuous emulsification runs before the stator seal reaches its thermal limit. Published torque values for this specific polymer configuration are limited, and equipment-specific validation is required.

When Solvent-Based Microencapsulation Requires Low Organic-Phase Viscosity

Oil-in-water emulsification is a primary route for preparing RG 502 H microspheres. The polymer is dissolved in dichloromethane at 10–30 wt%, the drug is either dissolved or dispersed in the organic phase, and the solution is injected or dispersed into an aqueous continuous phase containing 1–2% w/v polyvinyl alcohol at 2–8 °C. High-shear rotor-stator dispersers with tip speeds of 10–20 m/s are typically used to generate microspheres in the 10–100 µm size range. The low-viscosity acid-terminated grade allows higher polymer loading in the organic phase while maintaining droplet break-up under shear, which can improve encapsulation efficiency for hydrophobic drugs. However, higher polymer concentration also increases the residual solvent burden, and the hardening bath must be designed to remove dichloromethane without causing shell collapse.

The hardening step is a critical threshold. If solvent removal is too rapid, a dense polymer shell forms before the dispersed droplet has fully contracted, producing hollow or collapsed microspheres. If solvent removal is too slow, drug migration to the particle surface increases burst release and lowers encapsulation efficiency. Typical hardening protocols hold the emulsion below 4 °C for the first 2–3 h, then gradually warm to 25 °C under controlled stirring at 300–500 rpm. Residual dichloromethane after washing and lyophilization is typically targeted below 600 ppm because the ICH Q3C Class 2 limit for dichloromethane is 600 ppm. This is a finished-product specification, not a property of the polymer itself, but it drives the processing design for RG 502 H formulations.

For nanoparticle processing, the same low-viscosity grade can be used in nanoprecipitation or emulsion-solvent diffusion. A dilute organic phase of 5–10 wt% is injected into an aqueous surfactant phase, and the solvent is removed by vacuum stripping or dialysis. The acid end groups provide colloidal stability through electrostatic repulsion at neutral pH, but this effect is formulation-dependent and should not be substituted for appropriate surfactant or steric stabilization. The acid end groups can also interact with cationic lipids or amine-containing surfactants, which may reduce zeta potential and increase aggregation. Published data for this specific configuration is limited, and formulation-specific electrokinetic characterization is required.

The grade is also used in phase-inversion depot systems where a water-miscible solvent such as N-methyl-2-pyrrolidone or dimethyl sulfoxide is used to dissolve the polymer and drug. Upon injection into an aqueous environment, the solvent exchanges with water and the polymer precipitates as a depot. The low inherent viscosity of RG 502 H allows injection through smaller-gauge needles at lower force, but the trade-off is a faster water influx and often a higher initial burst than higher-viscosity grades. Burst release must be characterized by in vitro release testing under sink conditions; the test media and sampling intervals should be aligned with the intended route of administration.

Operational boundaries for RG 502 H include avoidance of long-term storage in organic solution, because even trace water can initiate ester hydrolysis. Stock solutions should be prepared under dry conditions, stored at −20 °C, and used within 24 h unless stability data support longer holding times. Melt processing should not exceed 120 °C because thermal depolymerization accelerates and may alter the lactide:glycolide ratio. If melt extrusion is used as a downstream blending step, twin-screw extruders with L/D ratios of 20:1 to 30:1 and barrel temperatures in the 80–110 °C range are more appropriate than injection molding, but solvent-based processing remains the primary route for this grade.

For biological qualification, the raw polymer is not a therapeutic product and cannot be evaluated as a finished device. Manufacturers must qualify the polymer as a starting material under ICH Q7 or ISO 13485 quality systems. Vendor documentation typically includes residual solvent, heavy metals, and endotoxin data, but final device evaluation is performed according to ISO 10993-1. Cytotoxicity testing is conducted on the finished article using ISO 10993-5, and parenteral products require endotoxin control per USP ⟨85⟩. Residual solvent and moisture limits are applied to the finished dosage form using USP ⟨467⟩ and USP ⟨921⟩, respectively, rather than being accepted solely from raw polymer certificates.